[go: up one dir, main page]

EP1218487A2 - Procedes et dispositifs permettant d'obtenir des cellules de lignee non hematopoietique a partir de cellules de progeniteurs hematopoietiques - Google Patents

Procedes et dispositifs permettant d'obtenir des cellules de lignee non hematopoietique a partir de cellules de progeniteurs hematopoietiques

Info

Publication number
EP1218487A2
EP1218487A2 EP00965306A EP00965306A EP1218487A2 EP 1218487 A2 EP1218487 A2 EP 1218487A2 EP 00965306 A EP00965306 A EP 00965306A EP 00965306 A EP00965306 A EP 00965306A EP 1218487 A2 EP1218487 A2 EP 1218487A2
Authority
EP
European Patent Office
Prior art keywords
cells
hematopoietic
hematopoietic progenitor
cell
progenitor cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00965306A
Other languages
German (de)
English (en)
Inventor
Mark J. Pykett
Michael Rosenzweig
Naheed Banu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytomatrix LLC
Original Assignee
Cell Science Therapeutics
Cytomatrix LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Science Therapeutics, Cytomatrix LLC filed Critical Cell Science Therapeutics
Publication of EP1218487A2 publication Critical patent/EP1218487A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C12N2501/392—Sexual steroids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells

Definitions

  • This invention relates generally to hematopoietic cells, and more specifically to methods and devices for obtaining non-hematopoietic lineage cells from hematopoietic progenitor cells.
  • Non-hematopoietic lineage cells obtained by the foregoing methods of the invention are useful in the therapeutic treatment of a variety of pathologic conditions in humans and other species.
  • the hematopoietic system is formed via a complex series of event at the molecular and cellular levels in which pluripotent hematopoietic stem cells give rise to mature, functional daughter cells.
  • Hematopoietic stem cells begin blood cell formation early in ⁇ . ⁇ embryogenesis, going through a series of anatomic moves that take them from the yolk sac to the liver and spleen and ultimately to the bone marrow, where they reside from the neonate stage through adulthood.
  • the hematopoietic cells interact with a variety of other cell types, including stromal/mesenchymal cells, endothelial cells, fat cells and bone cells, among others, to provide appropriate hematopoietic homeostasis.
  • hematopoietic progenitor (or stem) cells undergo a series of phenotypic changes that broadly correlate with functional capabilities.
  • stem cells have
  • CD34 + a cell surface molecule termed CD34 + .
  • HPCs hematopoietic progenitor cells
  • Hematopoietic progenitor cells are typically envisioned to reside in the bone marrow, although they can be isolated from umbilical cord and placental blood, from fetal liver and other fetal tissues such as the yolk sac, and from peripheral blood at low frequencies which can be increased by the administration of certain chemotherapeutic drugs.
  • a successful approach providing a common progenitor cell would greatly facilitate the production of a large number of further differentiated precursor cells of a specific lineage including non-hematopoietic cells, and in turn provide a larger number of differentiated cells with a wide variety of applications, including blood transfusions and cell-lineage specific cell reconstitutions including tissue regeneration and organ replacement.
  • An object of the invention is to provide methods and devices for the controlled production in large numbers of specific lineages of progenitor cells and their more differentiated cells.
  • the invention in one important part, involves methods and devices for obtaining non- hematopoietic lineage cells from hematopoietic progenitor cells.
  • one aspect of the invention is the variety of differentiated non-blood progeny cells and tissue, including in forms suitable for medical use, that can be obtained from a sample of hematopoietic progenitor cells.
  • hematopoietic progenitor cells are capable of forming an array of cell and tissue types, including mesenchymal, parenchymal, neuronal, endothelial, and epithelial cells.
  • the invention thus involves this unexpected tissue multipotency of hematopoietic progenitor cells.
  • differentiation can be carried out with greater efficiency in a three dimensional matrix culture device as compared to standard two-dimensional (or monolayer) culture devices.
  • the invention has therefore a variety of therapeutic applications in tissue repair, tissue transplantation, tissue re-implantation, tissue-specific expression of recombinant genes, and the like.
  • tissues include, but are not limited to, brain tissue, breast tissue, gastrointestinal tissue, ovarian tissue, and/or tissue of the following organs and/or systems: Blood and Blood Forming system: including platelets, blood vessel wall, and bone marrow; Cardiovascular system: including heart and vascular system; Digestive and excretory system: including alimentary tract, biliary tract, kidney, liver, pancreas and urinary tract; Endocrine system: including adrenal gland, kidney, ovary, pituitary gland, renal gland, salivary gland, sebaceous gland, testis, thymus gland and thyroid gland; Muscular system: including muscles that move the body; Reproductive System: including breast, ovary, penis and uterus; Respiratory system: including bronchus, lung and trachea; Skeletal system: including bones and joints; Tissue, fiber, and
  • a method for in vitro culture of hematopoietic progenitor cells to produce differentiated cells of non-hematopoietic lineage involves culturing hematopoietic progenitor cells in an environment that promotes hematopoietic progenitor cell differentiation, under conditions and for a period of time to produce differentiated cells of non-hematopoietic lineage.
  • the environment comprises factors that direct differentiation of hematopoietic progenitor cells to produce differentiated cells of non-hematopoietic lineage selected from the group consisting of mesenchymal, parenchymal, neuronal, endothelial, and epithelial cells.
  • the hematopoietic progenitor cells are CD34 " cells
  • the environment comprises growth factors selected from the group consisting of bFGF and TGF- ⁇ , to produce mesenchymal cells.
  • the hematopoietic progenitor cells are CD34 + and/or CD34 " cells, and the environment comprises growth factors selected from the group consisting of putrescine, progesterone, sodium selenite, insulin, transferrin, EGF, NGF, and bFGF, to produce neuronal eels.
  • the hematopoietic progenitor cells are CD34 + and/or CD34 " , and the environment comprises growth factors selected from the group consisting of IL-3, SCF, TGF- ⁇ l, and Flk-2/Flt-3 ligand, to produce epithelial cells.
  • the hematopoietic progenitor cells are CD34 + and/or CD34 " , and the environment comprises VEGF, to produce endothelial cells.
  • the hematopoietic progenitor cells are CD34 + and/or CD34 " , and the environment comprises EGF, bFGF, and SF/HGF, to produce parenchymal cells.
  • the environment comprises a solid, porous matrix having a unitary microstructure.
  • the environment comprises factors that direct differentiation of hematopoietic progenitor cells to produce differentiated cells of non- hematopoietic lineage selected from the group consisting of mesenchymal, parenchymal, neuronal, endothelial, and epithelial cells.
  • the cells are cultured upon and within a solid, porous matrix.
  • the porous matrix can be one that is an open cell porous matrix having a percent open space of at least 50%, and preferably at least 75%.
  • the porous solid matrix has pores defined by interconnecting ligaments having a diameter at midpoint, on average, of less than 150 ⁇ m.
  • the porous solid matrix is a metal- coated reticulated open cell foam of carbon containing material, the metal coating being selected from the group consisting of tantalum, titanium, platinum (including other metals of the platinum group), niobium, hafnium, tungsten, and combinations thereof.
  • the matrix is coated with a biological agent selected from the group consisting of collagens, fibronectins, laminins, integrins, angiogenic factors, anti-inflammatory factors, glycosaminoglycans, vitrogen, antibodies and fragments thereof, functional equivalents of these factors, and combinations thereof.
  • a biological agent selected from the group consisting of collagens, fibronectins, laminins, integrins, angiogenic factors, anti-inflammatory factors, glycosaminoglycans, vitrogen, antibodies and fragments thereof, functional equivalents of these factors, and combinations thereof.
  • the metal coating is tantalum coated with a biological agent.
  • the porous solid matrix having seeded hematopoietic progenitor cells and their progeny is impregnated with a gelatinous agent that occupies pores of the matrix.
  • the preferred embodiments of the invention are solid, unitary macrostructures, i.e. not beads or packed beads. They also involve nonbiodegradable materials.
  • the method further involves first isolating the hematopoietic cells from nonnucleated cells.
  • the method involves enriching the hematopoietic progenitor cells for a subpopulation of hematopoietic progenitor cells having a specific marker for a specific tissue, as described in greater detail below.
  • a method for producing a selected nonhematopoietic tissue from hematopoietic progenitor cells.
  • the method involves the in vitro culture of cells as described in detail above.
  • a method is provided for treating a subject. The method involves culturing hematopoietic progenitor cells as described above to produce nonhematopoietic cells and/or tissue, and then administering the nonhematopoietic cells and/or implanting the tissue into the subject.
  • the treatment may be administration of cells, and/or transplantation or reimplantation of cells or tissue.
  • hematopoietic progenitor cells may be genetically altered.
  • nonhematopoietic cells are administered into a subject intravenously.
  • the treatment may be for treating any number of disorders, all of which are described in greater detail below.
  • the various conditions of culture are as described above, as if fully repeated in this paragraph.
  • Figure 1 Graph of relative cell yields of hematopoietic cell-derived vimentin positive epithelial cells in three dimensional Cellfoam matrix cultures compared to plastic monolayer control cultures.
  • Figure 2 Graph of relative yields of hematopoietic cell-derived neurofilament positive neuronal cells in three dimensional Cellfoam matrix cultures compared to plastic monolayer control cultures.
  • FIG. 3 Flow cytometric analysis charts of CD34 " Lin " cells cultured for 4 weeks in three different cell growth media; Fig. 3A shows the presence of myeloid CD45 + CD33 + cells in hematopoietic cell growth media of the CD34 " Lin " cultures; Fig. 3B shows the presence of endothelial cells (left panel), and of epithelial cells (right panel) in the mesenchymal cell growth cultures of CD34 " Lin " cells; Fig. 3C shows the presence of neurofilament positive cells in the CD34 " Lin " cells cultured neural cell growth media (Left panel: isotype control; right panel: cultured cells).
  • FIG. 4 Flow cytometric analysis charts of brain cells from control (left panel), and transplanted mice with human CD34 " Lin “ cells (right panel), showing the detection of human s cell surface antigen expression (CD45).
  • Figure 5 PCR amplification results showing the presence or absence of human globin DNA in the brain and muscle transplanted and control mice.
  • SEQ ID NO: 1 is a human-specific globin PCR primer.
  • SEQ ID NO:2 is a human-specific globin PCR primer.
  • SEQ ID NO: 3 is a human-specific globin PCR primer.
  • the invention in one important part, involves methods and devices for obtaining nonhematopoietic lineage cells from hematopoietic progenitor cells.
  • one aspect of the invention is the variety of differentiated non-blood progeny cells that can be obtained from a sample of hematopoietic progenitor cells.
  • hematopoietic progenitor cells are capable of forming an array of cell and tissue types, including mesenchymal, parenchymal, neuronal, endothelial, and epithelial cells.
  • the invention thus involves this unexpected tissue multipotency of hematopoietic progenitor cells.
  • the invention in one important embodiment, involves culturing hematopoietic progenitor cells in a porous solid matrix.
  • a porous, solid matrix is defined as a three-dimensional structure with "sponge-like" continuous pores forming an interconnecting o network.
  • the matrix can be rigid or elastic, and it provides a scaffold upon which cells can grow throughout. Its pores are interconnected and provide the continuous network of channels extending through the matrix and also permit the flow of nutrients throughout.
  • a preferred matrix is an open cell foam matrix having a percent open space of at least 50% and preferably 75%. Thus, it is preferred that the open space comprise the majority of the matrix. This is believed to maximize cell migration, cell-cell contact, space for cell growth and accessibility to nutrients. It is preferred that the porous matrix be formed of a reticulated matrix of ligaments which at their center point are less than 150 ⁇ m in diameter, preferably
  • Suitable matrices can be obtained using a number of different methods. Examples of such methods include solvent casting or extraction of polymers, track etching of a variety of materials, foaming of a polymer, the replamineform process for hydroxyapatite, and other methodologies well known to those of ordinary skill in the art.
  • the materials employed can be natural or synthetic, including biological materials such as proteins, hyaluronic acids, synthetic polymers such as polyvinyl pyrolidones, polymethylmethacrylate, methyl cellulose, polystyrene, polypropylene, polyurethane, ceramics such as tricalcium phosphate, calcium aluminate, calcium hydroxyapatite and ceramic-reinforced or coated polymers. If the starting material for the scaffold is not metal, a metal coating can be applied to the three-dimensional matrix. Metal coatings provide further structural support and/or cell growth and adhesive properties to the matrix.
  • Preferred metals used as coatings comprise tantalum, titanium, platinum and metals in the same element group as platinum, niobium, hafnium, tungsten, and combinations of alloys thereof.
  • Coating methods for metals include a process such as CVD (Chemical Vapor Deposition).
  • the preferred matrix refered to herein throughout as Cellfoam, is described in detail in U.S. Patent No. 5,282,861, and is incorporated herein by reference (“Cellfoam", Cytomatrix, Woburn, MA).
  • the preferred matrix is a reticulated open cell substrate formed by a lightweight, substantially rigid foam of carbon- containing material having open spaces defined by an interconnecting network, wherein said foam material has interconnected continuous channels, and a thin film of metallic material deposited onto the reticulated open cell substrate and covering substantially all of the interconnecting network to form a composite porous biocompatible material creating a porous microstructure similar to that of natural cancellous bone.
  • such matrices can be coated with biological agents which can promote cell adhesion for the cultured hematopoietic cells, allowing for improved migration, growth and proliferation.
  • biological agents that promote angiogenesis (vascularization) and biological agents that prevent/reduce inflammation may also be used for coating of the matrices.
  • Preferred biological agents comprise collagens, fibronectins, laminins, integrins, angiogenic factors, anti-inflammatory factors, glycosaminoglycans, vitrogen, antibodies and fragments thereof, functional equivalents of these agents, and combinations thereof.
  • Angiogenic factors include platelet derived growth factor (PDGF), vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), bFGF-2, leptins, plasminogen activators (tPA, uPA), angiopoietins, lipoprotein A, transforming growth factor- ⁇ , bradykinin, angiogenic oligosaccharides (e.g., hyaluronan, heparan sulphate), thrombospondin, hepatocyte growth factor (also known as scatter factor) and members of the CXC chemokine receptor family.
  • PDGF platelet derived growth factor
  • VEGF vascular endothelial growth factor
  • bFGF basic fibroblast growth factor
  • bFGF-2 basic fibroblast growth factor-2
  • leptins plasminogen activators
  • tPA plasminogen activators
  • angiopoietins angiopoi
  • Anti-inflammatory factors comprise steroidal and non- steroidal compounds and examples include: Alclofenac; Alclometasone Dipropionate; Algestone Acetonide; Alpha Amylase; Amcinafal; Amcinafide; Amfenac Sodium; Amiprilose Hydrochloride; Anakinra; Anirolac; Anitrazafen; Apazone; Balsalazide Disodium; Bendazac; Benoxaprofen; Benzydamine Hydrochloride; Bromelains; Broperamole; Budesonide; Carprofen; Cicloprofen; Cintazone; Cliprofen; Clobetasol Propionate; Clobetasone Butyrate; Clopirac; Cloticasone Propionate; Cormethasone Acetate; Cortodoxone; Deflazacort; Desonide; Desoximetasone; Dexamethasone Dipropionate; Diclofenac Potassium; Diclofenac Sodium; Dif
  • Salsalate Sanguinarium Chloride ; Seclazone ; Sermetacin; Sudoxicam; Sulindac; Suprofen;
  • Tesicam Tesimide; Tetrydamine ; Tiopinac ; Tixocortol Pivalate; Tolmetin; Tolmetin j Sodium; Triclonide; Triflumidate; Zidometacin; Zomepirac Sodium.
  • Hematopoietic progenitor cells refer to immature blood cells having the capacity to self-renew and to differentiate into the more mature blood cells (also described herein as "progeny") comprising granulocytes (e.g., promyelocytes, 0 neutrophils, eosinophils, basophils), erythrocytes (e.g., reticulocytes, erythrocytes), thrombocytes (e.g., megakaryoblasts, platelet producing megakaryocytes, platelets), and monocytes (e.g., monocytes, macrophages).
  • Such cells may include CD34 + cells and/or CD34 " cells.
  • “Mature blood cells” refer to cells that express one or 5 more cell surface antigen(s) characteristic of a hematopoietic lineage cell.
  • Such cell surface antigen(s) are well known to those of ordinary skill in the art, and include CD33, CD19, CD61, CD71, CD42, CD66, CD66e, CD3, CD4, CD8, CD2, and CD20.
  • CD34 + cells are immature cells present in the "blood products" described below, express the CD34 cell surface marker, and are believed to include a subpopulation of cells o with the "progenitor cell” properties defined above.
  • the likewise immature CD34 " subset of bone marrow cells also possesses important progenitor cell capabilities, including the ability to reconstitute the hematopoietic system of animals. It is believed that CD34 " cells, which are more fibroblast-like in nature, begin to express CD34 during hematopoietic differentiation while simultaneously self-renewing into more CD34 " cells.
  • CD34 which are highly charged cell surface molecules
  • the CD34 " precursors are highly quiescent and exhibit better engraftment capabilities than CD34 + cells. As these cells mature, they acquire CD34 antigen, first at low levels and subsequently at higher levels, a progression associated with increasing maturity 0 and proliferative ability. It has also been reported that CD34 " cells are unresponsive to cytokines in traditional methylcellulose assays and do not form colonies.
  • the hematopoietic progenitor cells can be obtained from blood products.
  • a "blood product” as used in the present invention defines a product obtained from the body or an organ of the body containing cells of hematopoietic origin. Such sources include unfractionated bone marrow, umbilical cord, peripheral blood, liver, thymus, lymph and spleen. It will be apparent to those of ordinary skill in the art that all of the aforementioned crude or unfractionated blood products can be enriched for cells having "hematopoietic progenitor cell" characteristics in a number of ways. For example, the blood product can be depleted from the more differentiated progeny. The more mature, differentiated cells can be selected against, via cell surface molecules they express.
  • the blood product can be fractionated selecting for CD34 + cells.
  • CD34 + cells are thought in the art to include a subpopulation of cells capable of self-renewal and pluripotentiality. Such selection can be accomplished using, for example, commercially available magnetic anti-CD34 beads (Dynal, Lake Success, NY). Unfractionated blood products can be obtained directly from a donor or retrieved from cryopreservative storage.
  • the invention can preserve hematopoietic progenitor cells and to stimulate the expansion of hematopoietic progenitor cell number and/or colony forming unit potential.
  • the cells for example, can be differentiated into nonhematopoietic tissue and returned to the body to supplement, replenish, etc. a patient's nonhematopoietic progenitor cell population.
  • the invention thus is useful for therapeutic purposes and also is useful for research purposes such as in testing in animal or in vitro models of medical, physiological or metabolic pathways or conditions, and/or in the in vitro studying of cell differentiation.
  • hematopoietic progenitor cells produced according to the invention and stimulate them with hematopoietic growth agents that promote hematopoietic cell maintenance, expansion and/or differentiation, to yield the more mature blood and non-blood cells, in vitro.
  • Such expanded populations of blood and non-blood cells may be applied in vivo as described above, or may be used experimentally as will be recognized by those of ordinary skill in the art.
  • Such differentiated cells include those described above, and elsewhere herein.
  • the hematopoietic progenitor cells are continuously cultured for an extended period of time, and aliquots of the cultured cells are harvested spaced apart in time or intermittently.
  • "Harvesting hematopoietic cells” is defined as the dislodging or separation of cells from the matrix. This can be accomplished using a number of methods, such as enzymatic, centrifugal, electrical or by size, or the one preferred in the present invention, by flushing of the cells using the media in which the cells are incubated. The cells can be further collected and separated.
  • Harvesting steps spaced apart in time or “intermittent harvest of cells” is meant to indicate that a portion of the cells are harvested, leaving behind another portion of cells for their continuous culture in the established media, maintaining a continuous source of the original cells and their characteristics.
  • Harvesting "at least a portion of means harvesting a subpopulation of or the entirety of.
  • the invention can be used to expand the number of hematopoietic progenitor cells, all the while harvesting portions of those cells being expanded for treatment to develop even larger populations of differentiated cells.
  • the media used is that which is conventional for culturing cells.
  • examples include RPMI, DMEM, ISCOVES, etc.
  • these media are supplemented with human or animal plasma or serum.
  • plasma or serum can contain small amounts of hematopoietic growth factors.
  • the media used according to the present invention can depart from that used conventionally in the prior art.
  • hematopoietic progenitor cells can be cultured on the matrices described above for extended periods of time without the need for adding any exogenous growth agents (other than those which may be contained in plasma or serum, hereinafter "serum"), without inoculating the environment of the culture with stromal cells and without using stromal cell conditioned media.
  • the growth agents of particular interest in connection with the present invention are growth factors.
  • “Growth factors,” as used herein, refer to factors that influence the survival, proliferation or differentiation of hematopoietic cells to blood or non-blood cells.
  • Growth factors that promote differentiation of hematopoietic progenitor toward a non-blood cell lineage include, but are not limited to bFGF, TGF- ⁇ , TGF- ⁇ l, putrescine, progesterone, sodium selenite, insulin, transferrin, EGF, NGF, IL-3, SCF, and Flk-2/Flt-3 ligand, VEGF, SF/HGF and the like.
  • bFGF bFGF
  • TGF- ⁇ TGF- ⁇
  • TGF- ⁇ l putrescine
  • progesterone sodium selenite
  • insulin transferrin
  • EGF EGF
  • NGF IL-3
  • SCF IL-3
  • Flk-2/Flt-3 ligand Flk-2/Flt-3 ligand
  • VEGF SF/HGF and the like.
  • the hematopoietic progenitor cells are cultured in an environment that may include inoculated stromal cells, stromal cell conditioned medium and growth factors that promote and direct differentiation of hematopoietic cells toward a specific non-hematopoietic cell-lineage.
  • inoculated stromal cells it is meant that the cell culture includes stromal cells which have been introduced into the chamber as an inoculum for promoting survival, proliferation, and/or lineage-specific differentiation of the hematopoietic progenitor cells.
  • Fibroblasts as used herein comprise fibroblasts and mesenchymal cells, with or without other cells and elements, and can be seeded prior to, or substantially at the same time as, the hematopoietic progenitor cells, therefore establishing conditions that favor the subsequent attachment and growth of hematopoietic progenitor cells.
  • Fibroblasts can be obtained via a biopsy from any tissue or organ, and include fetal fibroblasts. These fibroblasts and mesenchymal cells may be transfected with exogenous DNA that encodes, for example, one of the hematopoietic growth factors described above.
  • “Stromal cell conditioned medium” refers to medium in which the aforementioned stromal cells have been incubated. The incubation is performed for a period sufficient to allow the stromal cells to secrete factors into the medium. Such "stromal cell conditioned medium” can then be used to supplement the culture of hematopoietic progenitor cells promoting their proliferation and/or lineage-specific differentiation according to the invention.
  • All of the foregoing stromal cells may be genetically manipulated so that they express a growth factor according to the invention, for example, a factor that directs hematopoietic progenitor cells toward a specific, hematopoietic and/or non-hematopoietic lineage.
  • the culture of the hematopoietic cells preferably occurs under conditions sufficient to increase the number of such cells, the colony forming potential of such cells, and/or the differentiation of such cells into hematopoietic and non-hematopoietic cell lineages.
  • the conditions used refer to a combination of conditions known in the art (e.g., temperature, CO 2 and O 2 content, nutritive media, etc.).
  • the time sufficient to increase the number of cells is a time that can be easily determined by a person skilled in the art, and can vary depending upon the original number of cells seeded. As an example, discoloration of the media can be used as an indicator of confluency.
  • different volumes of the blood product can be cultured under identical conditions, and cells can be harvested and counted over regular time intervals, thus generating the "control curves". These "control curves" can be used to estimate cell numbers in subsequent occasions.
  • Colony forming potential is the ability of a cell to form progeny. Assays for this are well known to those of ordinary skill in the art and include seeding cells into a semi-solid, treating them with growth factors and counting the number of colonies.
  • the method involves implanting cells produced according to the methods of the present invention into a subject.
  • the method involves implanting a porous solid matrix having pre-seeded hematopoietic progenitor cells and hematopoietic progenitor cell progeny. Implantation of matrices similar to the matrices of the invention is well known in the art (Stackpool, GJ, et al, Combined Orthopaedic Research Societies Meeting, Nov. 6-8, 1995, San Diego, CA, Abstract Book p. 45; Turner, TM, et al., 21st Annual Meeting of the Society for Biomaterials, March 18-22, San Francisco, CA, Abstract Book p. 125).
  • Such matrices are biocompatible (i.e., no immune reactivity-no rejection) and can be implanted and transplanted in a number of different tissues of a subject.
  • Such methods are useful in a variety of ways, including the study of hematopoietic progenitor cell maintenance, expansion and/or differentiation in vivo, in a number of different tissues of a subject, or in different subjects.
  • a subject is a human, non-human primate, cow, horse, pig, sheep, goat, dog, cat or rodent.
  • Human hematopoietic progenitor cells and human subjects are particularly important embodiments.
  • biological agents that promote angiogenesis (vascularization) and/or prevent/reduce inflammation may also be used for coating of the matrices.
  • Preferred biological agents are as described above.
  • the hematopoietic progenitor cells are pre-seeded onto the porous solid matrix and cultured in vitro according to the invention, before implantation into a subject.
  • an amount of the cells is introduced in vitro into the porous solid matrix, and cultured in an environment that may contain inoculated stromal cells, stromal cell conditioned medium, and exogenously added hematopoietic growth factors that promote hematopoietic cell maintenance, expansion and/or differentiation, other than serum. Implantation is then carried out.
  • the porous solid matrix having seeded hematopoietic progenitor cells, without or preferably with their differentiated non-blood cell progeny, is impregnated with a gelatinous agent that occupies pores of the matrix.
  • the hematopoietic progenitor cells, with or without their progeny are seeded prior to, substantially at the same time as, or following impregnation (or infiltration) with a gelatinous agent.
  • the cells may be mixed with the gelatinous agent and seeded at the same time as the impregnation of the matrix with the agent.
  • the hematopoietic progenitor cells, with or without their progeny are pre- seeded onto the porous solid matrix.
  • an amount of the cells is introduced in vitro into the porous solid matrix, and cultured in an environment that is free of inoculated stromal cells, stromal cell conditioned medium, and exogenously added hematopoietic growth factors that promote hematopoietic cell maintenance, expansion and/or differentiation, other than serum.
  • the "Impregnation" with a gelatinous agent serves as to contain the cells within the matrix, and also to help maintain and/or enhance cell attachment onto the matrix.
  • the "gelatinous” agent may be one that can be maintained in a fluid state initially, and after its application into the matrix, be gelatinized in situ in the matrix. Such gelatinization may occur in a number of different ways, including altering the agent's temperature, irradiating the agent with an energy source (e.g., light), etc.
  • the agent may exist in a continuum from a fluid state to a semi-solid (gelatinous) state to a solid state. An agent's final state and gelatinization will always depend upon the particular "gelatinous" agent used and its individual properties.
  • a preferred "gelatinous” agent is characterized also by its structural porosity, necessary for allowing the nutrients of the growth media to reach the cells throughout the matrix.
  • Exemplary “gelatinous” agents include cellulosic polysaccharides (such as cellulose, hemicellulose, methylcellulose, and the like), agar, agarose, albumin, algal mucin, mucin, mucilage, collagens, glycosaminoglycans, and proteoglycans (including their sulphated forms).
  • the gelatinous agent may impregnate the matrix completely, in some embodiments partially, and in other embodiments minimally, serving only as a coating of the outer surfaces of the matrix. The extent of the impregnation will largely depend upon the physical characteristics of the "gelatinous” agent of choice.
  • the "gelatinous” agent is methylcellulose and the impregnation is complete.
  • the invention also involves the unexpected discovery that differentiated cells of nonhematopoietic lineage produced from hematopoietic progenitor cells according to the methods of the invention, when administered intravenously to a subject they specifically "home-in” to a tissue comprising cells of a lineage similar to the lineage of the administered differentiated cell.
  • cells produced from hematopoietic progenitor cells e.g., from CD34 " Lin " cells
  • the invention is therefore particularly useful for the delivery of cells of a specific lineage to a tissue normally comprising such cells, and/or for the tissue-specific delivery of exogenous nucleic acids and polypeptides.
  • hematopoietic progenitor cells could be genetically altered (e.g., transduced) to express the polypeptide of choice, differentiated to a specific nonhematopoietic lineage according to any of the foregoing methods of the invention, and then administered to a subject in need of such treatment according to any acceptable methods of administration discussed elsewhere herein.
  • hematopoietic progenitor cells can be more efficiently transduced if the transduction occurs while the hematopoietic progenitor cells are on and within a solid porous matrix as described above.
  • the specific-lineage progeny would therefore express the transduced gene of interest.
  • transduction of hematopoietic cells refers to the process of transferring exogenous genetic material into a o cell of hematopoietic origin.
  • exogenous genetic material refers to nucleic acids or oligonucleotides, either natural or synthetic, that are introduced into the hematopoietic progenitor cells.
  • exogenous genetic material may be a copy of that which is naturally present in the cells, or it may not be naturally found in the cells. It typically is at least a portion of a naturally occuring gene which has been placed under operable control of a promoter in a vector construct.
  • nucleic acids may be introduced into cells. Such techniques include transfection of nucleic acid-CaPO precipitates, transfection of nucleic acids associated with DEAE, transfection with a retrovirus including the nucleic acid of interest, liposome mediated transfection, and the like. For certain uses, it is preferred to target the nucleic acid to particular cells.
  • a vehicle used for delivering a nucleic acid according to the invention into a cell e.g., a retrovirus, or other virus; a liposome
  • a targeting molecule attached thereto.
  • a molecule such as an antibody i specific for a surface membrane protein on the target cell or a ligand for a receptor on the target cell can be bound to or incorporated within the nucleic acid delivery vehicle.
  • proteins which bind to a surface membrane protein associated with endocytosis may be incorporated into the liposome formulation for targeting and/or to facilitate uptake.
  • proteins include o proteins or fragments thereof tropic for a particular cell type, antibodies for proteins which undergo internalization in cycling, proteins that target intracellular localization and enhance intracellular half life, and the like.
  • Polymeric delivery systems also have been used successfully to deliver nucleic acids into cells, as is known by those skilled in the art.
  • the preferred method of introducing exogenous genetic material into hematopoietic cells is by transducing the cells in situ on the matrix using replication- deficient retro viruses.
  • Replication-deficient retroviruses are capable of directing synthesis of all virion proteins, but are incapable of making infectious particles. Accordingly, these genetically altered retroviral vectors have general utility for high-efficiency transduction of genes in cultured cells, and specific utility for use in the method of the present invention. Retroviruses have been used extensively for transferring genetic material into cells.
  • Standard protocols for producing replication-deficient retroviruses including the steps of incorporation of exogenous genetic material into a plasmid, transfection of a packaging cell line with plasmid, production of recombinant retroviruses by the packaging cell line, collection of viral particles from tissue culture media, and infection of the target cells with the viral particles) are provided in the art.
  • the major advantage of using retroviruses is that the viruses insert efficiently a single copy of the gene encoding the therapeutic agent into the host cell genome, thereby permitting the exogenous genetic material to be passed on to the progeny of the cell when it divides.
  • gene promoter sequences in the LTR region have been reported to enhance expression of an inserted coding sequence in a variety of cell types.
  • the major disadvantages of using a retrovirus expression vector are (1) insertional mutagenesis, i.e., the insertion of the therapeutic gene into an undesirable position in the target cell genome which, for example, leads to unregulated cell growth and (2) the need for target cell proliferation in order for the therapeutic gene carried by the vector to be integrated into the target genome.
  • adenovirus a double-stranded DNA virus.
  • the adenovirus genome is adaptable for use as an expression vector for gene transduction, i.e., by removing the genetic information that controls production of the virus itself. Because the adenovirus functions usually in an extrachromosomal fashion, the recombinant adenovirus does not have the theoretical problem of insertional mutagenesis.
  • adenoviral transformation of a target hematopoietic cell may not result in stable transduction.
  • certain adenoviral sequences confer intrachromosomal integration specificity to carrier sequences, and thus result in a stable transduction of the exogenous genetic material.
  • suitable vectors are available for transferring exogenous genetic material into hematopoietic cells.
  • the selection of an appropriate vector to deliver a therapeutic agent for a particular condition amenable to gene replacement therapy and the optimization of the conditions for insertion of the selected expression vector into the cell, are within the scope of one of ordinary skill in the art without the need for undue experimentation.
  • the promoter characteristically has a specific nucleotide sequence necessary to initiate transcription.
  • the exogenous genetic material further includes additional sequences (i.e., enhancers) required to obtain the desired gene transcription activity.
  • enhancers i.e., enhancers
  • the exogenous genetic material is introduced into the hematopoietic cell genome immediately downstream from the promoter so that the promoter and coding sequence are operatively linked so as to permit transcription of the coding sequence.
  • a preferred retroviral expression vector includes an exogenous promoter element to control transcription of the inserted exogenous gene.
  • exogenous promoters include both constitutive and inducible promoters.
  • constitutive promoters control the expression of essential cell functions. As a result, a gene under the control of a constitutive promoter is expressed under all conditions of cell growth.
  • exemplary constitutive promoters include the promoters for the following genes which encode certain constitutive or "housekeeping" functions: hypoxanthine phosphoribosyl transferase (HPRT), dihydrofolate reductase (DHFR) (Scharfmann et al., Proc. Natl. Acad. Sci.
  • any of the above-referenced constitutive promoters can be used to control transcription of a heterologous gene insert.
  • inducible promoters Genes that are under the control of inducible promoters are expressed only or to a greater degree, in the presence of an inducing agent, (e.g., transcription under control of the metallothionein promoter is greatly increased in presence of certain metal ions).
  • Inducible promoters include responsive elements (REs) which stimulate transcription when their inducing factors are bound.
  • REs responsive elements
  • Promoters containing a particular RE can be chosen in order to obtain an inducible response and in some cases, the RE itself may be attached to a different promoter, thereby conferring inducibility to the recombinant gene.
  • the expression vector preferably includes a selection gene, for example, a neomycin resistance gene, for facilitating selection of hematopoietic cells that have been transfected or transduced with the expression vector.
  • a selection gene for example, a neomycin resistance gene
  • the hematopoietic cells are transfected with two or more expression vectors, at least one vector containing the gene(s) encoding the therapeutic agent(s), the other vector containing a selection gene.
  • the selection and optimization of a particular expression vector for expressing a specific gene product in an isolated hematopoietic cell is accomplished by obtaining the gene, preferably with one or more appropriate control regions (e.g., promoter, insertion sequence); preparing a vector construct comprising the vector into which is inserted the gene; transfecting or transducing cultured hematopoietic cells in vitro with the vector construct; and determining whether the gene product is present in the cultured cells.
  • appropriate control regions e.g., promoter, insertion sequence
  • MDR Advanced cancer Human multiple-drug resistance
  • Metastatic melanoma Genetically engineered autologous tumor vaccines 9/10/93 producing ⁇ nterleuk ⁇ n-2
  • Metastatic breast cancer Non-viral system for delivering human 9/12/94 (refractory or recurrent) mterleukin-2 gene into autologous tumor cells
  • Table 1 represent only examples of genes that can be delivered according to the methods of the invention. Suitable promoters, enhancers, vectors, etc., for such genes are published in the literature associated with the foregoing trials.
  • useful genes replace or supplement function, including genes encoding missing enzymes such as adenosine deaminase (ADA) which has been used in clinical trials to treat ADA deficiency and cofactors such as insulin and coagulation factor VIII.
  • Genes which affect regulation can also be administered, alone or in combination with a gene supplementing or replacing a specific function
  • the invention is particularly useful in delivering genes which stimulate the immune response, including genes encoding viral antigens, tumor antigens, cytokines (e.g. tumor necrosis factor) and inducers of cytokines (e.g. endotoxin)
  • genes which stimulate the immune response including genes encoding viral antigens, tumor antigens, cytokines (e.g. tumor necrosis factor) and inducers of cytokines (e.g. endotoxin)
  • the invention provides methods for treating subjects with
  • therapeutics e.g., cells and tissues obtained according to the present invention, and for conditions described below and elsewhere herein.
  • the therapeutics of the invention are administered in effective amounts.
  • an effective amount will depend upon the mode of administration, the particular condition being treated and the desired outcome. It will also depend upon, the stage of the condition, the age and physical condition of the subject, the nature of concurrent therapy, if any, and like factors well known to the medical practitioner. For therapeutic applications, it is that amount sufficient to achieve a medically desirable result. In some cases, for example, this is an increase in tissue repair. In other cases, this is an increase in wound healing repair. In further cases, this is an increase in tissue-specific production of a particular protein.
  • a variety of administration routes are available.
  • the methods of the invention may be practiced using any mode of administration that is medically acceptable, meaning any mode that produces effective levels of the active compounds without causing clinically unacceptable adverse effects.
  • modes of administration include surgical, oral, rectal, topical, nasal, intradermal, or parenteral routes.
  • parenteral includes subcutaneous, intravenous, intramuscular, or infusion.
  • a preferred method of administration of cells produced according to any of the methods of the invention is intravenous administration.
  • Neuronal cells are predominantly categorized based on their local/regional synaptic connections (e.g., local circuit interneurons vs. longrange projection neurons) and receptor sets, and associated second messenger systems.
  • Neuronal cells include both central nervous system (CNS) neurons and peripheral nervous system (PNS) neurons.
  • CNS central nervous system
  • PNS peripheral nervous system
  • neuronal cell types include, but are not limited to, sensory and sympathetic neurons, cholinergic neurons, dorsal root ganglion neurons, proprioceptive neurons (in the trigeminal mesencephalic nucleus), ciliary ganglion neurons (in the parasympathetic nervous system), etc.
  • a person of ordinary skill in the art will be able to easily identify neuronal cells and distinguish them from non-neuronal cells such as glial cells, typically utilizing cell-morphological characteristics, expression of cell- specific markers, secretion of certain molecules, etc. Differentiating a neuronal cell from another and/or a non-neuronal cell is less important than trying to treat according to the invention the particular region of the nervous system affected (including specific brain regions, e.g., frontal, parietal, temporal, or occipital lobe, and spinal cord regions, e.g., sacral, lumbar, thoracic, or cervical regions, etc.).
  • specific brain regions e.g., frontal, parietal, temporal, or occipital lobe
  • spinal cord regions e.g., sacral, lumbar, thoracic, or cervical regions, etc.
  • Neurodegenerative disorder is defined herein as a disorder in which progressive loss of neurons occurs either in the peripheral nervous system or in the central nervous system.
  • neurodegenerative disorders include: (i) chronic neurodegenerative diseases such as familial and sporadic amyotrophic lateral sclerosis (FALS and ALS, respectively), familial and sporadic Parkinson's disease, Huntington's disease, familial and sporadic Alzheimer's disease, multiple sclerosis, olivopontocerebellar atrophy, multiple system atrophy, progressive supranuclear palsy, diffuse Lewy body disease, corticodentatonigral degeneration, progressive familial myoclonic epilepsy, strionigral degeneration, torsion dystonia, familial tremor, Down's Syndrome, Gilles de la Tourette syndrome, Hallervorden-Spatz disease, diabetic peripheral neuropathy, dementia pugilistica, AIDS Dementia
  • FALS and ALS amyotrophic lateral sclerosis
  • neurodegenerative disorder Most of the chronic neurodegenerative diseases are typified by onset during the middle adult years and lead to rapid degeneration of specific subsets of neurons within the neural system, ultimately resulting in premature death.
  • the invention involves treatment of subjects with: Vascular disorders such as arteriosclerosis, coronary artery disease, aortic aneurysm, arterial diseases of the lower extremities, cerebral vascular disease, congenital or structural vessel defect, inflammatory or granulometers;
  • Vascular disorders such as arteriosclerosis, coronary artery disease, aortic aneurysm, arterial diseases of the lower extremities, cerebral vascular disease, congenital or structural vessel defect, inflammatory or granulometers;
  • Vessel defects disorders of the smaller vessels; such as hypersensitivity or autoimmune diseases.
  • Other diseases associated with early arteriosclerosis including diabetes mellitus, hypertension, familial hypercholesterolemia, familial combined hyperlipidemia, hypothyroidism, cholesterol storage disease, systemic lupus erythematosis, cystemia, chronic renal insufficiency, chronic vitamin D intoxication, cytoelastocomb itopathic arteriocalsification, aortic valvular calcification.
  • aortic aneurysm as may be caused by artherosclerosis, cystic medial netrosis, siphilitic infection, mycotic infection or rheumatic aortitis or trauma.
  • Aortic dissection may be caused by cystic medial necrosis, systemic hypertension, arteriosclerosis.
  • Aortic occlusion may be caused by arteriosclerosis, thromboembolism, Giant cell arthritis.
  • Arterial diseases that effect the extremities including arteriosclerosis, fibromuscular dysplasia, thromboengitis obliterans, vasculitis, acute arteriosclerocclusion,
  • Venous disorders of the extremities include venous thrombosis, deep venous thrombosis, superficial veins thrombosis, varicose veins.
  • Examples where epithelial cells may be used include replacement of urine tract and bladder epiphelium, replacement of skin epithelia, replacement of corneal epithelium, and/or eplacement of intestinal epithelia.
  • o Disorders of the skin include: eczema, psoriasis, papulos sqamis disorders such as: psoriosis, lichenplanus, peteriosis rosia, immunoelectrical mediated skin diseases such as: pamphogus volgarus, pamphogus pholiatious, pamphogoid, dermatitis hapetiformus, epidermal olysis beloza equista, dermatomyocytis, lupus erothemotosis, scleroderma and morphia, burns, ulcers, chromatic lesions, large surgical wounds. s The invention will be more fully understood by reference to the following examples.
  • Example 1 Production of non-hematopoietic lineage cells from hematopoietic progenitor cells
  • the culture devices used in the present invention included: 1) a biocompatible, three dimensional matrix arranged as a series of continuous channels and interconnected pores with a porosity of approximately 90%) ("Cellfoam", Cytomatrix, Woburn, MA) coated with full length fibronectin before culture of cells; or 2) multiwell plastic dishes (Corning-Costar, Acton, MA) coated with full length fibronectin (full length fibronectin from Boehringer o Mannheim, Germany).
  • Hematopoietic stem cells obtained from commercially purchased human bone marrow samples were purified by density gradient centrifugation or primary bone marrow preparations over Ficoll 1066 (Sigma, St. Louis, MO). 5 In instances in which CD34 + and CD34 " cells were separated, the Ficoll-purified preparations were run over a magnetic cell separation column (Miltenyi Biotec, Auburn, CA). To establish the cultures, 66- 160xl0 5 CD34 + cells were seeded onto the plastic 48-well dishes coated with fibronectin (plastic), or into fibronectin-coated Cellfoam (Cytomatrix) also in 48 well dishes. Culture Media
  • Cultures utilized various types of media designed to promote the tissue-specific maturation of the HSCs.
  • HSC cultures CD34 + or CD34 " cells were cultured in RPMI (Sigma) supplemented with 10% fetal bovine serum (FBS) (Sigma), penicillin (10 IU/mL), streptomycin (10 ⁇ g/mL), L-glutamine (1 mM), Hepes (10 mM), fungizone (2.5 ⁇ g/ ⁇ L) and the hematopoietic growth factors IL-3 (20 ng/mL), SCF (50 ng/mL) and Flk-2/Flt-3 ligand (50 ng/mL) (all cytokines were from Stem Cell Technologies, Vancouver, CANADA).
  • FBS fetal bovine serum
  • CD34 mesenchymal cell directed differentiation
  • DMEM low glucose, Life Technologies, Gaithersburg, MD
  • penicillin 10 IU/mL
  • streptomycin 10 ⁇ g/mL
  • L- glutamine 1 mM
  • Hepes 10 mM
  • fungizone 2.5 ⁇ g/ ⁇ L
  • growth factors bFGF 50 ng/mL
  • R&D Systems Minneapolis, MN
  • TGF- ⁇ 50 pg/mL
  • CD34 + cells were cultured in DMEM/F12 medium 1 :1 (Life Technologies) containing ), penicillin (10 IU/mL), streptomycin (10 ⁇ g/mL), L-glutamine (1 mM), Hepes (10 mM), fungizone (2.5 ⁇ g/ ⁇ L), putrescine (9.6 ng/mL), progesterone (6.3 ng/mL), sodium selenite (5.2 ng/mL), insulin (0.025 mg/mL), transferrin (0.1 mg/mL), EGF (20 ng/mL), NGF (20 ng/mL), and bFGF (20 ng/mL) (all from Sigma).
  • CD34 For epithelial cell directed differentiation cultures, CD34 " cells were cultured using the same medium formulation as for mesenchymal with the additional supplementation of IL-3 (20 ng/mL), SCF (50 ng/mL), TGF- ⁇ l (50 pg/mL), and Flk-2/Flt-3 ligand (50 ng/mL).
  • Endothelial Cell Directed Differentiation For endothelial cell directed differentiation cultures, CD34 " cells were cultured using the same medium formulation as for mesenchymal cells with the additional supplementation of vascular endothelial growth factor (VEGF) (30 ng/mL) (Pharmingen, NJ). Parenchymal Cell Directed Differentiation: For parenchymal cell directed differentiation cultures, CD34 " cells were cultured using the same medium formulation as for mesenchymal cells with the additional supplementation of EGF, bFGF, and scatter factor (also known as hepatocyte growth factor (SF/HGF). In all of the foregoing conditions, half media changes were performed twice a week.
  • VEGF vascular endothelial growth factor
  • Nonadherent cells from plastic (2D) culture devices coated with fibronectin were collected by gentle washing and adherent cells were collected with CDS by incubation 10 minutes at 37°C. Both adherent and nonadherent cells were pooled and viable cells were counted.
  • Hematopoietic cells were identified based on anti-CD34 (QbendlO, Immunotech,
  • Dickinson monoclonal antibodies to evaluate progenitor cell distributions.
  • Mesenchymal cells were identified based on vimentin expression using an anti- vimentin monoclonal antibody (Sigma, St. Louis, MO).
  • Neuronal cells were identified based on expression of neurofilament protein using an anti-neuro filament monoclonal antibody (Sigma, St. Louis, MO).
  • Epithelial cells were identified based on cytokeratin expression using an anti- cytokeratin antibody (Sigma, St. Louis, MO). Endothelial cells were identified based on von Willebrand factor expression using an anti-von Willebrand factor monoclonal antibody (Coulter Immunotech, Pittsburgh, PA).
  • Parenchymal cells can be identified based on a number of different methods well known to those of ordinary skill in the art. For example, kidney cells can be characterized by positive expression of erythropoetin, liver cells can be characterized by positive expression of albumin, beta-islet cells of the pancreas can be characterized by positive expression of insulin, etc.
  • CD34 " cells isolated as the eluent from CD34 + purification procedures were cultured in flasks overnight to allow the adherence of cells to the plastic. The following day, the non-adherent CD34 " fraction was isolated and placed into Cellfoam cultures. Cells were harvested at 3 and 6 weeks, and the cells analyzed for functional activity in CFU assays. Interestingly, these cells did not form standard myeloid or erythroid colonies, even when additional cytokines (SCF, IL3 and Flk-2 ligand) were added. Instead, they yielded small, fibroblast-like colonies comprised of small, atypical cells only.
  • SCF cytokines
  • CD34 " lin " cells were isolated from human bone marrow using a magnetic cell separation system (Miltenyi) followed by selection over a column for lineage-positive v. lineage-negative cells.
  • the cell population yielded from the CD34 + / " selection process followed by the lineage depletion step was homogeneous, being typically greater than 97% CD34 + or CD34 ' (depending on the approach), >95%> CD45%> and
  • epithelial-cell specific medium RPMI media supplemented with 10% FBS plus IL-3 (20ng/ml), SCF (50 ng/ml), FLK-2/FLT-3 ligand (50 ng/ml), bFGF (50ng/ml
  • CD34 " lin” cells were also cultured at 140,000 cells per well in 5 the three dimensional device coated with fibronectin (fibronectin-coated Cellfoam). After 7 weeks of culture under the conditions that induce differentiation into vimentin+ mesenchymal cell (DMEM low glucose, 10% FBS, penicillin (10 IU/mL), streptomycin (10 ⁇ g/mL), L- glutamine (1 mM), Hepes (10 mM), fungizone (2.5 ⁇ g/ ⁇ L) plus the growth factors bFGF (50 ng/mL) and TGF-beta (50 pg/mL), cells were harvested and adherent and nonadherent cells o were pooled together.
  • DMEM low glucose, 10% FBS, penicillin (10 IU/mL), streptomycin (10 ⁇ g/mL), L- glutamine (1 mM), Hepes (10 mM), fungizone (2.5 ⁇ g/ ⁇ L) plus the growth factors bFGF (50
  • CD34 + lin " cells were isolated from human bone marrow and 100,000 cells per well were cultured in the three dimensional matrix Cellfoam under conditions that induce the formation 0 of neurofilament "1" neural cells (DMEM/F-12 media supplemented with 10% FBS, progesterone (6.3 ng/ml), putrescine (9.6 ng/ml), sodium selenite (5.2 ng/ml), insulin (0.025 mg/ml) and transferrin (0.10 ng/ml)). After 4 weeks of culture, cells were harvested and stained with antibodies against CD45 and the intracellular neuronal cell neurofilament protein.
  • the slides with affixed cells were then removed, air dried and stained with a standard hematoxylin/eosin staining. The slides were then scored by qualified technicians for the presence of the targeted tissue- specific cell types.
  • the culture of CD34 + or CD34 " hematopoietic cells (depending on the condition) in media that induced the differentiation of the specified nonhematopoietic cell types led to the detectable presence of cells with the typical morphology of the targeted cell type.
  • culture of CD34 " cells under mesenchymal cell conditions led to the formation of a large number of cells with mesenchymal-like appearance that had large, fusiform bodies with centrally placed, round nuclei and tapered cytoplasmic processes at their ends.
  • CD34 " cells from primary bone marrow samples were cultured in the mesenchymal cell-specific medium (DMEM base supplemented with mesenchymal specific cytokines as noted above)
  • the three dimensional cultures routinely yielded more CD45 " (non-hematopoietic) vimentin+ (mesenchymal) cells than plastic cultures.
  • CD45 non-hematopoietic vimentin+ (mesenchymal) cells than plastic cultures.
  • Cellfoam cultures produced between 3.5 and 12 times as many cells with this lineage-specific phenotype as plastic cultures did in 5 out of 5 replicates (conditions A-E).
  • the three dimensional matrix cultures produced significantly more CD45 " (non-hematopoietic) neurofilament + (neuronal) cells than plastic cultures.
  • the three dimensional matrix cultures yielded up to 160 fold more cells in multiple replicates as plastic under the neuronal-cell specific culture conditions (DMEM/F12).
  • R-10+HSC neuronal cell specific conditions
  • Example 2 Production of non-hematopoietic lineage cells from CD34 ' Lin hematopoietic progenitor cells and in vivo homing of the non-hematopoietic lineage cells to a tissue of interest
  • Normal human bone marrow cells or light density mononuclear cells were purchased from Poietic Technologies (Gaithersburg, MD). In case of whole bone marrow cells mononuclear cells were isolated by diluting the samples 1 :3 with RPMI- 1640 media followed by Ficoll-hispaque density (1.077 mg/cm 3 ) centrifugation separation (Sigma).
  • Light density mononuclear cells were resuspended in phosphate-buffered saline (PBS) without Ca + , Mg + supplemented with 2% FBS and incubated at room temperature for 15 minutes with a mixture of CD2, CD3, CDl lb, CD14, CD15, CD16, CD19 CD24, CD33, CD41, CD56, CD66b, and Glycophorin-A tetrameric antibody complexes (StemCell Technologies, Vancouver, British Columbia, Canada). These tetrameric complexes are bispecific cross-linkers that bind that described antigen and dextran. After washing excess antibodies, 20 nm magnetic colloidal iron dextran particles were added and incubated at room temperature for 15 minutes.
  • PBS phosphate-buffered saline
  • DMEM mesenchymal stem cells
  • DMEM low glucose
  • Penicillin 10 IU/ML
  • Streptomycin 10 ⁇ g/ml
  • L-glutamine ImM
  • Hepes lOmM
  • Fungizone 2.5 ⁇ g/ml
  • Dexamethasone 0.05 mM L-Ascorbic acid, lOmM ⁇ -Glycerophosphate and bFGF at 50 ng/ml (R&D system, Minneapolis, MN), TGF- ⁇ at 50 pg/ml (R&D system, Minneapolis, MN), EGF at 25 ng/ml and VEGF at 10 ng/ml.
  • DMEM/F-12 media (Life Technologies, Gaithersburg, MD) supplemented with 10%> Fetal Bovine Serum (Sigma), Penicillin (10 IU/ML), Streptomycin (10 ⁇ g/ml), L-glutamine (ImM), Hepes (lOmM), Fungizone 2.5 ⁇ g/ml (Life Technologies, Gaithersburg, MD), Putrescine at 9.6 ng/mg (Sigma, St. Louis, MO), Progesterone at 6.3 ng/ml (Sigma, St. Louis, MO), Sodium Selenite at 5.2 ng/ml (Sigma, St.
  • Non-adherent cells were harvested from three-dimensional Cellfoam devices by centrifugation for 10 minutes at 1500 rpm (approx. 250 G).
  • Adherent cells from three dimensional culture devices were collected by incubating cellfoam with Cell Dissociation Solution (Sigma, St. Louis, MO) for 30 minutes at 37°C or treated with trypsin for 10 minutes at 37°C and terminating the reaction with FCS and then centrifuging at 1500 rpm for 10 minutes.
  • Nonadherent cells from plastic coated with fibronectin cultures were collected by gentle washing and adherent cells were collected with CDS by incubation 10 minutes at 37°C. Both adherent and nonadherent cells were pooled and viable cells were counted.
  • Human cell preparation in vitro cultures 500,000 CD34 " Lin " cells were seeded into 6 well fibronectin coated dishes. Cells were cultured for 4 weeks in neuronal growth medium and growth factors with half of medium change biweekly. After harvest as described above, adherent and nonadherent cells were pooled and resuspended in PBS as 350,000/0.300 ml. Mice: NOD/SCID mice 4-6 weeks old were purchased from Jackson Laboratories (Maine). Mice were irradiated with 325 cGy of total body irradiation from coblt 60 source. After 24 hours of radiation, mice were injected with above mentioned human cells or PBS as control. All mice were handled under sterile condition and maintained in cage microisolators.
  • mice were sacrificed 18 days postransplantation by cervical dislocation. Brain was isolated immediately followed by thymus, spleen, bone marrow, and muscle. Cell preparation from different tissues: i) Preparation of Brain cells: All the isolation process was performed using an ice cold sterile PBS, GKN buffers made by adding 8 g/L NaCl, 0.4g/L KC1, 3.56 g/L NaHPO 4 . 12H 2 O, 0.78 g/L NaH 2 PO4.2H 2 O, 2g/L and D-(+) glucose, pH 7.4. Before isolation 0.02% (w/v) isotonic BSA was added into GKN buffer.
  • Mice brains were isolated within minimum time and kept in ice-cold GKN buffer+0.02% BAS and divided into two pieces. Half of the brain was fixed with formalin for IHC. The other half was used to isolate cells for FACS and PCR. Mechanically the brain was dissociated into pieces with forcepts and passed through 70 ⁇ m filter unit and collected in a 50 ml tube and washed by centrifugation for 10 min at 400g.
  • the pellet was digested emzymatically with collagenase and Dnase for 60 min at 37°C. During the digestion the cells were resuspended with pipette tips. After digestion the cells were washed twice with 40 ml of GKN/BSA buffer. The cells were resuspended in 10 ml of Percoll 1.03 g/ml and underlayered with 5 ml of 1.095 g/ml of Percoll and overlayed with 5 ml of GKN/BSA buffer. Centrifugation was done for 30 min at 20°C at 1250Xg with break off position.
  • Muscle Tissues were divided into two. Half was fixed with 36% formalin for IHC and other half was used to isolate the cells. Half of the muscle tissues, thymus, and spleen were minced with stainless scissors separately and grinned. Spleen and thymus were filtered through 70 ⁇ m filter unit and collected separately. The muscle cell pellet was treated with 0.2%) Collagenase at 45°C for 45 minutes. After inhibiting trypsin with FBS, cells were washed and passed through 70 ⁇ m filter unit. iii) Preparation of bone marrow cells:
  • Bone marrow cells were obtained by flushing the shafts of the bones with 2%> FBS containing PBS using 1 ml syringe and 21 gauge and 27 gauge needles. Flow cytometry analysis After 3 to 6 weeks of culture, all cells (adherent and non-adherent) were harvested from all culture conditions, counted, and stained with fluorochrome-conjugated antibodies to surface antigens and in some cases for intracellular filamentous proteins.
  • Antibodies used for surface phenotype determination included anti-CD34 (QbendlO, Immunotech, Westbrook, Maine), anti-CD38 (Becton Dickinson, San Jose, CA) and-CD45 (Becton Dickinson) antibodies to evaluate progenitor cell distributions.
  • Cells were stained in the presence of staining buffer (PBS with 2% fetal bovine serum). After staining, the cells were fixed with 2% paraformaldehyde.
  • Fix and Perm kit from Caltag Laboratories (Burlingame, CA) and antibodies to neurofilament (DAKO, Carpintera, CA), Von Willebrand's factor (Coulter-Immunotech, Miami, Florida), Cytokeratin and Vimentin (Sigma, St. Louis, MO) were used following the stained protocol of the manufacturer.
  • hematopoietic colony assays equal numbers of cells isolated from Cellfoam or plastic/FN coated cultures, as described above, were added to 6.67xl0 4 cells/ml to 3.0 ml of methylcellulose medium with cytokines (IL-3 20 ng/ml: erythropoietin 3 IU/ml; stem cell factor 50 ng/ml; all Stem Cell Technologies, Vancouver) plus 0.5 ml of DMEM (2% FCS, 10 IU/ml penicillin, 10 ⁇ g/ml streptomycin, 1 MM L-glutamine).
  • cytokines IL-3 20 ng/ml: erythropoietin 3 IU/ml; stem cell factor 50 ng/ml; all Stem Cell Technologies, Vancouver
  • Genomic DNA was prepared from cells using the QIAamp DNA Mini Kit (Qiagen, Santa Clarita, CA). Human-specific primer sequences were: 5'-GGGCAAGGTGAAGG TGAACGTGGATGA-3' (SEQ ID NO:l) and 5'-CCATCACTAAAGGCACCGAGC-3' (SEQ ID NO:2) and 5'-GTCACCAGCAGGCAGTGGCT-3' (SEQ ID NO:3). All primers were synthesized by GIBCO/BRL.
  • PCR conditions were: 94°C for 2 min, followed by 95°C, 30 s, 58°C 30 s and 72°C, 45 s for 38 cycles. One second per cycle was added to the elongation time for the final 28 cycles.
  • Each PCR reaction contained 2 U of Expand polymerase mix (Boehringer Mannheim, Germany), 0.2 mM dNTPs, 1.5 mM MgCl 2 , and 12.5 ⁇ M each primer.
  • CD34 " Lin” cells isolated from human adult bone marrow were used in cultures specific for hematopoietic stem cell (HSC), mesenchymal stem cell (MSC) and neural stem cell (NSC) differentiation. CD34 + Lin “ cells were also collected and treated in same was as CD34 " Lin " cells. After 3 to 4 weeks, the cultures were harvested and evaluated by flow cytometry.
  • HSC hematopoietic stem cell
  • MSC mesenchymal stem cell
  • NSC neural stem cell
  • MSC cultures which consisted of MSC growth medium and growth factors, resulted in the development CD45 " Cytokeratin + (epithelial) and CD45 " Vimetin + (mesesnchymal) cells with CD34 " lin " cell.
  • CD45 Cytokeratin + (epithelial)
  • CD45 Vimetin + (mesesnchymal) cells
  • CD34 lin cell.
  • vascular endothelial growth factor was added to the culture medium, cells expressing von Willebrands Factor were detected in the MSC cultures as indicated by Figure 3B (left panel).
  • CD34 + Lin " cells did not express any epithelial cell or endothelial cells surface markers.
  • Non-adherent cells expressing the hematopoietic phenotype CD45 + CD34 + CD38 + were isolated from hematopoietic growth culture medium supplemented with hematopoietic growth factors using both CD34 " lin " and CD34 + Lin " cells.
  • CD34Xin cells cultured in neuronal growth medium supplemented with neuronal growth factors were observed to express neurofilament ( Figure 3C).
  • the morphology of the cultured CD34 " lin " cells in these three growth specific culture media was also markedly different. Long adherent cells were extensive complex process as were seen in neuronoal cultures.
  • Adherent, spindle shaped cells were observed in MSC cultures. Round nonadherent were observed in hematopoietic cultures.
  • bone marrow derived CD34 " lin " cells appear to contain a primitive precursor cell or pool of cells which can be manipulated ex vivo to differentiate into a particular non hematopoietic tissue type.
  • bone marrow CD34 " Lin” cells cultured for 4 weeks under conditions for neuronal cell differentiation were injected via the tail vein into irradiated NOD/SCID mice. After 18 days, the mice were sacrificed and cells from the brain, muscle, thymus, spleen, and bone marrow were collected and stained with antibodies specific to human CD45 and MHC Class- 1.
  • Figure 4 shows the presence of human cells (CD45 + and/or MHC Class 1 + ) in the brain of transplanted mice.
  • HSC, MSC and NSC may originate from a common precursor or pool of precursors in human bone marrow. These precursor cells may have strong requirements for defined growth environments to enable their differentiation into particular lineages. The data also suggests that the homing of the injected cells is organ specific.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des cellules hématopoïétiques et plus spécifiquement des procédés et des dispositifs qui permettent d'obtenir des cellules de lignée non hématopoïétique à partir de cellules de progéniteurs hématopoïétiques. Les cellules de lignée non hématopoïétique obtenues au moyen des procédés selon l'invention présentés ci-avant sont utiles dans le traitement thérapeutique d'une grande diversité de troubles pathologiques chez l'homme et chez d'autres espèces.
EP00965306A 1999-09-23 2000-09-22 Procedes et dispositifs permettant d'obtenir des cellules de lignee non hematopoietique a partir de cellules de progeniteurs hematopoietiques Withdrawn EP1218487A2 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15603199P 1999-09-23 1999-09-23
US156031P 1999-09-23
US21743800P 2000-07-10 2000-07-10
US217438P 2000-07-10
PCT/US2000/026020 WO2001021766A2 (fr) 1999-09-23 2000-09-22 Procedes et dispositifs permettant d'obtenir des cellules de lignee non hematopoietique a partir de cellules de progeniteurs hematopoietiques

Publications (1)

Publication Number Publication Date
EP1218487A2 true EP1218487A2 (fr) 2002-07-03

Family

ID=26852807

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00965306A Withdrawn EP1218487A2 (fr) 1999-09-23 2000-09-22 Procedes et dispositifs permettant d'obtenir des cellules de lignee non hematopoietique a partir de cellules de progeniteurs hematopoietiques

Country Status (2)

Country Link
EP (1) EP1218487A2 (fr)
WO (1) WO2001021766A2 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440734B1 (en) 1998-09-25 2002-08-27 Cytomatrix, Llc Methods and devices for the long-term culture of hematopoietic progenitor cells
US6548299B1 (en) * 1999-11-12 2003-04-15 Mark J. Pykett Lymphoid tissue-specific cell production from hematopoietic progenitor cells in three-dimensional devices
US8609412B2 (en) 1999-08-05 2013-12-17 Regents Of The University Of Minnesota Mapc generation of lung tissue
US8075881B2 (en) 1999-08-05 2011-12-13 Regents Of The University Of Minnesota Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure
CA2852534A1 (fr) 1999-08-05 2001-02-15 Abt Holding Company Cellules souches adultes toutes-puissantes et procede d'isolement
US10638734B2 (en) 2004-01-05 2020-05-05 Abt Holding Company Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
US8252280B1 (en) 1999-08-05 2012-08-28 Regents Of The University Of Minnesota MAPC generation of muscle
JP2004529621A (ja) 2001-02-14 2004-09-30 ティー ファークト，レオ 多能性成体幹細胞、その起源、それを得る方法および維持する方法、それを分化させる方法、その使用法、ならびにそれ由来の細胞
KR100449141B1 (ko) * 2001-04-19 2004-09-21 (주)라이프코드 간엽 간세포를 신경세포로 분화시키는 방법
ES2180433B1 (es) * 2001-05-28 2004-05-16 Universidad Miguel Hernandez De Elche. Empleo de celulas madre hematopoyeticas en la generacion de celulas madre neurales.
WO2003055989A2 (fr) 2001-12-21 2003-07-10 Mount Sinai Hospital Compositions cellulaires et procedes de preparation et d'utilisation associes
AU2003250666A1 (en) 2002-07-29 2004-02-16 Asahi Kasei Kabushiki Kaisha Stem cells for treating pancreatic damage
US20060228798A1 (en) 2002-11-27 2006-10-12 Catherine Verfaillie Homologous recombination in multipotent adult progenitor cells
AU2003303071B2 (en) 2002-12-16 2009-04-23 Technion Research & Development Foundation Ltd. Methods of preparing feeder cells-free, xeno-free human embryonic stem cells and stem cell cultures prepared using same
WO2005003320A2 (fr) 2003-07-02 2005-01-13 Regents Of The University Of Minnesota Differenciation neuronale de cellules souches
NZ567082A (en) 2005-10-14 2012-08-31 Univ Minnesota Differentiation of non-embryonic stem cells to cells having a pancreatic phenotype
US9005964B2 (en) 2006-11-24 2015-04-14 Regents Of The University Of Minnesota Endodermal progenitor cells
WO2008070902A1 (fr) * 2006-12-11 2008-06-19 Novozymes Biopharma Au Limited Compositions de tgf-bêta destinées au traitement de l'infertilité
ES2326772B1 (es) * 2007-09-26 2010-07-26 Fundacion Progreso Y Salud Procedimiento de obtencion de celulas madre mesenquimales con capacidad pluripotente.
US20110111492A1 (en) 2008-01-18 2011-05-12 Regents Of The University Of Minnesota Stem Cell Aggregates and Methods for Making and Using
AU2009327485A1 (en) 2008-06-18 2010-06-24 Cytopherx, Inc. Methods for propagation of renal precursor cells
US9057051B2 (en) 2008-10-31 2015-06-16 Katholieke Universiteit Leuven Optimized methods for differentiation of cells into cells with hepatocyte progenitor phenotypes, cells produced by the methods, and methods of using the cells
EP2568991B3 (fr) 2010-05-12 2018-11-28 ABT Holding Company Modulation des splénocytes en thérapie cellulaire
US9090878B2 (en) 2010-06-17 2015-07-28 Katholieke Universiteit Leuven Methods for differentiating cells into hepatic stellate cells and hepatic sinusoidal endothelial cells, cells produced by the methods, and methods for using the cells
SG10201914007YA (en) 2010-08-24 2020-03-30 Univ Minnesota Non-static suspension culture of cell aggregates
EP2625264B1 (fr) 2010-10-08 2022-12-07 Terumo BCT, Inc. Procédés et systèmes de culture et de récolte de cellules dans un système de bioréacteur à fibres creuses avec conditions de régulation
US9861660B2 (en) 2013-04-12 2018-01-09 Saverio LaFrancesca Organs for transplantation
EP3068867B1 (fr) 2013-11-16 2018-04-18 Terumo BCT, Inc. Expansion de cellules dans un bioréacteur
JP6783143B2 (ja) 2014-03-25 2020-11-11 テルモ ビーシーティー、インコーポレーテッド 培地の受動的補充
WO2016049421A1 (fr) 2014-09-26 2016-03-31 Terumo Bct, Inc. Alimentation programmée
WO2017004592A1 (fr) 2015-07-02 2017-01-05 Terumo Bct, Inc. Croissance cellulaire à l'aide de stimuli mécaniques
WO2017205667A1 (fr) 2016-05-25 2017-11-30 Terumo Bct, Inc. Expansion cellulaire
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
EP3656841A1 (fr) 2017-03-31 2020-05-27 Terumo BCT, Inc. Expansion cellulaire
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
JP2024511064A (ja) 2021-03-23 2024-03-12 テルモ ビーシーティー、インコーポレーテッド 細胞捕獲及び増殖
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2304650A1 (fr) * 1997-09-25 1999-04-01 Cytomatrix, Llc Procedes et dispositifs de culture a long terme de cellules souches hematopoietiques
CA2310852A1 (fr) * 1997-11-26 1999-06-03 University Of Southern California Procede favorisant la proliferation et la differentiation des cellules hematopoitiques et mesenchymateuses
ES2296413T3 (es) * 1998-06-08 2008-04-16 Osiris Therapeutics, Inc. Regulacion de la diferenciacion de celulas madre hematopoyeticas por el uso de celulas madre mesenquimaticas humanas.
WO2000017326A1 (fr) * 1998-09-21 2000-03-30 Musc Foundation For Research Development Cellules non hematopoietiques, y compris les cardiomyocytes et les cellules de muscle squelettique, que l'on derive de cellules souches hematopoietiques, et procedes relatifs a leur elaboration et a leur utilisation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO0121766A3 *

Also Published As

Publication number Publication date
WO2001021766A2 (fr) 2001-03-29
WO2001021766A3 (fr) 2001-06-28
WO2001021766A8 (fr) 2001-05-10
WO2001021766A9 (fr) 2001-07-26

Similar Documents

Publication Publication Date Title
EP1218487A2 (fr) Procedes et dispositifs permettant d'obtenir des cellules de lignee non hematopoietique a partir de cellules de progeniteurs hematopoietiques
US6440734B1 (en) Methods and devices for the long-term culture of hematopoietic progenitor cells
EP1135463B1 (fr) Production de cellules lymphoides specifiques d'un tissu a partir de cellules souches hematopoietiques se trouvant dans des dispositifs tridimensionnels
EP1627914A2 (fr) Procédés et dispositifs de culture à long terme de cellules souches hématopoïétiques
EP1084230B1 (fr) Regulation de la differenciation de cellules souches hematopoietiques au moyen de cellules souches mesenchymateuses humaines
JP4526186B2 (ja) 造血幹細胞を試験管内で維持する方法と組成物
Wang et al. Cell-to-cell contact induces mesenchymal stem cell to differentiate into cardiomyocyte and smooth muscle cell
Herbertson et al. Dexamethasone alters the subpopulation make‐up of rat bone marrow stromal cell cultures
US20110182866A1 (en) Isolation of stem cell precursors and expansion in non-adherent conditions
EP1447443A1 (fr) Cellules mesenchymateuses immortalisees et leur utilisation
US20170313983A1 (en) Multipotent stem cells and uses thereof
JPWO2006090882A1 (ja) 血管内皮前駆細胞の生体外増幅方法
JPWO2006093172A1 (ja) 成体幹細胞の体外増幅方法
KR20020013480A (ko) 사람 뇌의 내피세포 및 성장배지 및 원시 ｃｄ34+ｃｄ38-골수 간세포의 증가방법
Miao et al. Megakaryocyte–bone marrow stromal cell aggregates demonstrate increased colony formation and alkaline phosphatase expression in vitro
Hall et al. Phenotypic differentiation of TGF-β1-responsive pluripotent premesenchymal prehematopoietic progenitor (P4 stem) cells from murine bone marrow
WO2009035612A2 (fr) Cellules souches pluripotentes et leurs utilisations
KR20050042046A (ko) 조혈 줄기세포의 증식방법
WO2021227573A1 (fr) Milieu de culture exempt de xeno et procédé de multiplication de cellules souches mésenchymateuses au moyen de celui-ci
CN110511909B (zh) 体外扩增造血干细胞的生长因子组合物及其应用
JP2007508023A (ja) 間葉幹細胞由来の血液生成物

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020423

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CYTOMATRIX, LLC

17Q First examination report despatched

Effective date: 20030820

17Q First examination report despatched

Effective date: 20030820

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ROSENZWEIG, MICHAEL

Inventor name: PYKETT, MARK, J.

Inventor name: BANU, NAHEED

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070731